SEEL – Seelos Therapeutics Inc
Seelos Therapeutics, Inc.SEEL
$1.28Name : Seelos Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.00000000000000
EPSttm :
Seelos Therapeutics, Inc.
$1.28
0.00%$1.28Float Short %
46.13
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
989.44
EPS This/Next Y
Price
0.39
Target Price
Analyst Recom
1
Performance Q
-85.02
Relative Volume
Beta
1.87
Ticker: SEEL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-11 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-12 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-15 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-16 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-17 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-18 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-19 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-22 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-23 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-26 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-29 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-30 | SEEL | 0.39 | N/A | N/A | 0 |
| 2025-12-31 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-02 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-05 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-06 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-07 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-08 | SEEL | 0.39 | N/A | N/A | 0 |
| 2026-01-09 | SEEL | 0.39 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
No data found
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-1.48
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
Beta
1.87
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
14
Growth Score
Sentiment Score
9
Actual DrawDown %
100
Max Drawdown 5-Year %
-100
Target Price
P/E
Forward P/E
PEG
P/S
0.37
P/B
P/Free Cash Flow
EPS
351.04
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
-33.1
Return on Equity vs Industry %
-20.9
EPS 1 7Days Diff
4.1
EPS 1 30Days Diff
4.09
EBIT Estimation
Seelos Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 8
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
stock quote shares SEEL – Seelos Therapeutics Inc Stock Price stock today
news today SEEL – Seelos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SEEL – Seelos Therapeutics Inc yahoo finance google finance
stock history SEEL – Seelos Therapeutics Inc invest stock market
stock prices SEEL premarket after hours
ticker SEEL fair value insiders trading